Filter posts

The latest from GlobeImmune

Interview with Timothy C. Rodell, M.D., GlobeImmune CEO & President: Can you describe the top …

Anadys brings together the best of both worlds

Dr. Steve Worland, Ph.D., Anadys Pharmaceuticals, Inc. President, CEO, & Director, discusses the latest developments …

U.S. Patent for Resolvin to Enter Human Trials

Resolvyx Pharmaceuticals, Inc. announced the U.S. Patent and Trademark Office has granted a patent (U.S. …

What's New at ImmunoVaccine Technologies

An interview with Dr. Randal Chase, President & CEO of ImmunoVaccine Technologies: Can you describe …

A Word with Calistoga Pharmaceuticals' CEO

An interview with Dr. Carol Gallagher, Pharm.D., CEO of Calistoga Pharmaceuticals: Can you describe the …

XOMA to Repay Goldman Sachs Loan in Full

XOMA Ltd. (Nasdaq:XOMA) announced a plan to repay its loan with Goldman Sachs Specialty Holdings, …

Newron Announces Positive Results for Ralfinamide

Newron Pharmaceuticals SpA, announced positive preclinical study results showing that ralfinamide has statistically significant benefits …

Flu Study Finds Only One H1N1 Vaccine Shot Needed

Early results from clinical trials show that the majority of healthy adults may only need …

Team at BrainCells using brain cells

An interview with James A. Schoeneck, Chief Executive Officer, BrainCells, Inc.: Can you describe the …

Anadys Pharmaceuticals Begins Phase II Study Dosing of ANA598

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that dosing has begun in a Phase II …